HomeCompareRPFG vs ABBV

RPFG vs ABBV: Dividend Comparison 2026

RPFG yields 125000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPFG wins by $1019369930368.51M in total portfolio value
10 years
RPFG
RPFG
● Live price
125000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1019369930368.61M
Annual income
$390,340,295,156,222,850.00
Full RPFG calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RPFG vs ABBV

📍 RPFG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPFGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPFG + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPFG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPFG
Annual income on $10K today (after 15% tax)
$10,625,000.00/yr
After 10yr DRIP, annual income (after tax)
$331,789,250,882,789,440.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RPFG beats the other by $331,789,250,882,768,400.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPFG + ABBV for your $10,000?

RPFG: 50%ABBV: 50%
100% ABBV50/50100% RPFG
Portfolio after 10yr
$509684965184.36M
Annual income
$195,170,147,578,123,800.00/yr
Blended yield
38.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RPFG
No analyst data
Altman Z
-0.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPFG buys
0
ABBV buys
0
No recent congressional trades found for RPFG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPFGABBV
Forward yield125000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$1019369930368.61M$102.3K
Annual income after 10y$390,340,295,156,222,850.00$24,771.77
Total dividends collected$957112100063.81M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RPFG vs ABBV ($10,000, DRIP)

YearRPFG PortfolioRPFG Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$6,260,700$6,250,000.00$11,550$430.00+$6.25MRPFG
2$1,835,174,416$1,828,475,467.29$13,472$627.96+$1835.16MRPFG
3$252,418,700,426$250,455,063,800.57$15,906$926.08+$252418.68MRPFG
4$16,367,654,356,744$16,097,566,347,288.20$19,071$1,382.55+$16367654.34MRPFG
5$505,279,215,990,186$487,765,825,828,469.50$23,302$2,095.81+$505279215.97MRPFG
6$7,576,920,202,151,404$7,036,271,441,041,906.00$29,150$3,237.93+$7576920202.12MRPFG
7$57,412,205,565,343,256$49,304,900,949,041,250.00$37,536$5,121.41+$57412205565.31MRPFG
8$236,008,385,134,812,700$174,577,325,179,895,420.00$50,079$8,338.38+$236008385134.76MRPFG
9$587,878,163,749,896,600$335,349,191,655,647,000.00$69,753$14,065.80+$587878163749.83MRPFG
10$1,019,369,930,368,612,400$390,340,295,156,222,850.00$102,337$24,771.77+$1019369930368.51MRPFG

RPFG vs ABBV: Complete Analysis 2026

RPFGStock

Rainier Pacific Financial Group Inc. operates as the holding company for Rainier Pacific Savings Bank, which provides various banking services. Its deposit products include checking accounts, money market deposit accounts, savings accounts, certificates of deposit, and individual retirement accounts. The company's lending products include one-to-four family, multifamily, and commercial real estate loans; real estate construction loans, such as residential construction loans, single family land acquisition and development loans, and lot inventory loans; and consumer installment loans, such as auto, boats, recreational, home equity, and personal loans, as well as unsecured personal lines of credit, home equity lines of credit, and credit cards. In addition, it provides automobile and homeowners' insurance, financial planning, and non-federally insured mutual fund and investment services. The company provides its services to consumers, small and medium-sized businesses, and professionals. As of June 30, 2009, it operated 14 branch offices in the Tacoma-Pierce County market and the City of Federal Way, Washington State. The company was founded in 1932 and is based in Tacoma, Washington.

Full RPFG Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RPFG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPFG vs SCHDRPFG vs JEPIRPFG vs ORPFG vs KORPFG vs MAINRPFG vs JNJRPFG vs MRKRPFG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.